耐多药和广泛耐药结核病：当前概念和未来挑战的综述。
Multidrug-resistant and extensively drug-resistant tuberculosis: a review of current concepts and future challenges.
机构信息
Division of Clinical Infectious Diseases, Medical Clinic, Research Center Borstel, Borstel, Germany, and Department of Medicine, University of Namibia School of Medicine, Windhoek, Namibia
出版信息
Clin Med (Lond). 2014 Jun;14(3):279-85. doi: 10.7861/clinmedicine.14-3-279.
Abstract
Multidrug-resistant and extensively drug-resistant tuberculosis are recent global health issues, which makes tuberculosis - after the success of short course treatment during the second half of the last century - a major health challenge. Globalisation, health inequalities, competing economic interests and political instability contribute substantially to the spread of drug-resistant strains, which are associated with high rates of morbidity and mortality. Issues such as increasing transmission of drug-resistant strains, poor diagnostic coverage and a lengthy, toxic treatment need to be overcome by innovative approaches to tuberculosis control, prevention, diagnostics and treatment. This review addresses recent developments and future concepts.
摘要
耐多药和广泛耐药结核病是最近出现的全球卫生问题，使得结核病成为继上世纪后半叶成功实施短程化疗之后的一个主要卫生挑战。全球化、卫生不平等、相互竞争的经济利益和政治不稳定极大地助长了耐药菌株的传播，这些菌株与高发病率和死亡率相关。耐药菌株传播增加、诊断覆盖面差以及治疗过程漫长且毒性大等问题，需要通过创新方法来控制结核病、预防结核病、诊断结核病和治疗结核病。本综述讨论了最近的发展和未来的概念。
相似文献
1
Multidrug-resistant and extensively drug-resistant tuberculosis: a review of current concepts and future challenges.耐多药和广泛耐药结核病：当前概念和未来挑战的综述。
Clin Med (Lond). 2014 Jun;14(3):279-85. doi: 10.7861/clinmedicine.14-3-279.
2
Drug-resistant tuberculosis transmission and resistance amplification within families.耐药结核病在家庭内的传播和耐药性扩增。
Emerg Infect Dis. 2012 Aug;18(8):1342-5. doi: 10.3201/eid1808.111650.
3
Increasing drug resistance in extensively drug-resistant tuberculosis, South Africa.南非广泛耐药结核病的耐药性不断增加。
Emerg Infect Dis. 2011 Mar;17(3):510-3. doi: 10.3201/eid1703.101363.
4
Pre-extensively drug-resistant tuberculosis spondylodiscitis in an immunocompetent patient: a case report.免疫功能正常患者的广泛耐药结核性脊柱骨髓炎：病例报告。
Pan Afr Med J. 2020 Jul 8;36:165. doi: 10.11604/pamj.2020.36.165.21689. eCollection 2020.
5
Totally drug-resistant tuberculosis in India.印度的完全耐药结核病
Clin Infect Dis. 2012 Feb 15;54(4):579-81. doi: 10.1093/cid/cir889. Epub 2011 Dec 21.
6
Extensively drug-resistant tuberculosis: current challenges and threats.广泛耐药结核病：当前的挑战与威胁
FEMS Immunol Med Microbiol. 2008 Jul;53(2):145-50. doi: 10.1111/j.1574-695X.2008.00400.x. Epub 2008 May 8.
7
Drug Resistance Patterns of Multidrug- and Extensively Drug-Resistant Tuberculosis in Korea: Amplification of Resistance to Oral Second-line Drugs.韩国耐多药和广泛耐药结核病的耐药模式：对口服二线药物耐药性的增强
Ann Lab Med. 2017 Jul;37(4):323-326. doi: 10.3343/alm.2017.37.4.323.
8
Xpert MTB/RIF for Diagnosis of Tuberculosis and Drug Resistance in Indian Children.用于诊断印度儿童结核病及耐药性的Xpert MTB/RIF检测
Indian Pediatr. 2016 Sep 8;53(9):837-838. doi: 10.1007/s13312-016-0943-8. Epub 2016 Jul 1.
9
Multidrug-resistant/extensively drug-resistant tuberculosis in Greece: predominance of Mycobacterium tuberculosis genotypes endemic in the Former Soviet Union countries.希腊的耐多药/广泛耐药结核病：前苏联国家流行的结核分枝杆菌基因型占主导地位。
Clin Microbiol Infect. 2017 Dec;23(12):1002-1004. doi: 10.1016/j.cmi.2017.07.002. Epub 2017 Jul 8.
10
Tuberculosis and high altitude. Worth a try in extensively drug-resistant tuberculosis?结核病与高海拔。在广泛耐药结核病中值得一试吗？
Am J Respir Crit Care Med. 2014 Feb 15;189(4):390-3. doi: 10.1164/rccm.201311-2043OE.
引用本文的文献
1
Antimycobacterial and immunomodulatory activities of sorafenib in a preclinical mouse model of TB infection through CD4CD25 and CD8CD25 effector T cells.索拉非尼在结核感染临床前小鼠模型中通过CD4CD25和CD8CD25效应T细胞发挥的抗分枝杆菌及免疫调节活性。
Front Immunol. 2025 Jul 23;16:1591026. doi: 10.3389/fimmu.2025.1591026. eCollection 2025.
2
Epidemiology and Molecular Drug-Resistance Patterns of Tuberculosis in Non-Elderly Patients in Luoyang, China, 2019-2023.2019 - 2023年中国洛阳非老年患者结核病的流行病学及分子耐药模式
Infect Drug Resist. 2025 Jun 24;18:3087-3101. doi: 10.2147/IDR.S524300. eCollection 2025.
3
Isoniazid-historical development, metabolism associated toxicity and a perspective on its pharmacological improvement.异烟肼——历史发展、代谢相关毒性及其药理学改进展望
Front Pharmacol. 2024 Sep 19;15:1441147. doi: 10.3389/fphar.2024.1441147. eCollection 2024.
4
Drug susceptibility testing and line probe assay of first-line anti-tuberculosis drugs among presumptive tuberculosis patients attending a secondary care hospital in Bhubaneswar.布巴内斯瓦尔一家二级护理医院中疑似结核病患者一线抗结核药物的药敏试验和线性探针分析
J Family Med Prim Care. 2024 Jun;13(6):2491-2498. doi: 10.4103/jfmpc.jfmpc_736_23. Epub 2024 Jun 14.
5
Rv0100: An essential acyl carrier protein from M. tuberculosis important in dormancy.Rv0100：结核分枝杆菌中一种重要的休眠必需酰基载体蛋白。
PLoS One. 2024 Jun 7;19(6):e0304876. doi: 10.1371/journal.pone.0304876. eCollection 2024.
6
Antimycobacterial and healing effects of Pranlukast against MTB infection and pathogenesis in a preclinical mouse model of tuberculosis.普仑司特对 MTB 感染及肺结核病临床前小鼠模型发病机制的抗分枝杆菌和愈合作用。
Front Immunol. 2024 May 2;15:1347045. doi: 10.3389/fimmu.2024.1347045. eCollection 2024.
7
The use of nanoparticles in the treatment of infectious diseases and cancer, dental applications and tissue regeneration: a review.纳米颗粒在传染病和癌症治疗、牙科应用及组织再生中的应用：综述
Front Med Technol. 2024 Jan 23;5:1330007. doi: 10.3389/fmedt.2023.1330007. eCollection 2023.
8
Synthesis and structure-activity relationships of aryl fluorosulfate-based inhibitors as novel antitubercular agents.基于芳基氟硫酸酯的抑制剂的合成及构效关系研究作为新型抗结核药物。
Bioorg Med Chem Lett. 2024 Jan 15;98:129596. doi: 10.1016/j.bmcl.2023.129596. Epub 2023 Dec 23.
9
Multidrug-Resistant TB (MDR-TB) and Extensively Drug-Resistant TB (XDR-TB) Among Children: Where We Stand Now.儿童中的耐多药结核病（MDR-TB）和广泛耐药结核病（XDR-TB）：我们目前的状况
Cureus. 2023 Feb 18;15(2):e35154. doi: 10.7759/cureus.35154. eCollection 2023 Feb.
10
Safety, Tolerability, Pharmacokinetics, and Metabolism of Telacebec (Q203) for the Treatment of Tuberculosis: a Randomized, Placebo-Controlled, Multiple Ascending Dose Phase 1B Trial.泰乐菌素（Q203）治疗结核病的安全性、耐受性、药代动力学和代谢：一项随机、安慰剂对照、多次递增剂量的 1B 期临床试验。
Antimicrob Agents Chemother. 2023 Jan 24;67(1):e0112322. doi: 10.1128/aac.01123-22. Epub 2022 Dec 12.
本文引用的文献
1
Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement.欧洲耐多药/广泛耐药结核病患者的管理：一份欧洲结核病研究和培训网络（TBNET）共识声明
Eur Respir J. 2014 Jul;44(1):23-63. doi: 10.1183/09031936.00188313. Epub 2014 Mar 23.
2
A trial of mass isoniazid preventive therapy for tuberculosis control.大规模异烟肼预防治疗结核病控制的试验。
N Engl J Med. 2014 Jan 23;370(4):301-10. doi: 10.1056/NEJMoa1214289.
3
Principles for designing future regimens for multidrug-resistant tuberculosis.耐多药结核病未来治疗方案的设计原则
Bull World Health Organ. 2014 Jan 1;92(1):68-74. doi: 10.2471/BLT.13.122028. Epub 2013 Oct 25.
4
Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment?治疗药物管理：它会是耐多药结核病治疗的未来吗？
Eur Respir J. 2013 Dec;42(6):1449-53. doi: 10.1183/09031936.00073213.
5
Nomenclature of drug-resistant tuberculosis.耐多药结核病的命名
Lancet Infect Dis. 2013 Nov;13(11):917. doi: 10.1016/S1473-3099(13)70291-3.
6
Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study.耐多药结核病患儿接触者的预防治疗：一项前瞻性队列研究。
Clin Infect Dis. 2013 Dec;57(12):1676-84. doi: 10.1093/cid/cit655. Epub 2013 Sep 24.
7
Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation.结核病在欧盟的疾病负担：一项系统分析和成本计算。
Eur Respir J. 2014 Feb;43(2):554-65. doi: 10.1183/09031936.00079413. Epub 2013 Aug 15.
8
Effect of household and community interventions on the burden of tuberculosis in southern Africa: the ZAMSTAR community-randomised trial.家庭和社区干预对南部非洲结核病负担的影响：ZAMSTAR 社区随机试验。
Lancet. 2013 Oct 5;382(9899):1183-94. doi: 10.1016/S0140-6736(13)61131-9. Epub 2013 Aug 1.
9
High-dose fluoroquinolones in short-course regimens for treatment of MDR-TB: the way forward?短程治疗耐多药结核病的高剂量氟喹诺酮类药物：未来之路？
Int J Tuberc Lung Dis. 2013 Jul;17(7):853-4. doi: 10.5588/ijtld.13.0301.
10
A poor drug-resistant tuberculosis programme is worse than no programme: time for a change.一个糟糕的耐多药结核病防治项目比没有项目更糟糕：是时候做出改变了。
Int J Tuberc Lung Dis. 2013 Jun;17(6):714-8. doi: 10.5588/ijtld.12.0989. Epub 2013 Apr 9.
Zotero 插件